Relationship between expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in esophageal carcinoma cell lines

Diseases of the Esophagus

Volumn 21, Issue 1, 2008, Pages 15-20

  Ando, T ^a   Ishiguro, Hideyuki ^a   Kuwabara, Y ^a   Kimura, M ^a   Mitsui, A ^a   Sugito, N ^a   Mori, R ^a   Ogawa, R ^a   Katada, T ^a   Fujii, Y ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

Dihydropyrimidine dehydrogenase; Esophageal squamous cell carcinoma; Quantitative reverse transcriptase polymerase chain reaction; Thymidylate synthase

Indexed keywords

DIHYDROPYRIDINE DERIVATIVE; FLUOROURACIL; OROTATE PHOSPHORIBOSYLTRANSFERASE; THYMIDINE PHOSPHATE; THYMIDYLATE SYNTHASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IC 50; MOLECULAR PHYLOGENY; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; DIHYDROURACIL DEHYDROGENASE (NADP); ESOPHAGEAL NEOPLASMS; FLUOROURACIL; GENE EXPRESSION; HUMANS; INHIBITORY CONCENTRATION 50; OROTATE PHOSPHORIBOSYLTRANSFERASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

EID: 38049165566     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2007.00700.x     Document Type: Article

References (31)

1. Longley D B, Harkin D P, Johnston P G. 5-fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330-8.
2. Inokuchi M, Uetake H, Shirota Y, Yamada H, Tajima M, Sugihara K. Gene expression of 5-fluorouracil metabolic enzymes in primary colorectal cancer and corresponding liver metastasis. Cancer Chemother Pharmacol 2004; 53: 391-6.
3. Fujiwara H, Terashima M, Irinoda T et al. Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT-PCR. Jpn J Cancer Res 2002; 93: 1342-50.
4. Shintani Y, Ohta M, Hirabayashi H et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluorouracil in patients with non-small-cell lung cancer. Lung Cancer 2004; 45: 189-96.
5. Peters G J, Backus H H, Freemantle S et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002; 1587: 194-205.
6. Diasio R B, Johnson M R. Dihydropyrimidine dehydrogenase: Its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res 1999; 5: 2672-3.
7. Allegra C J. Dihydropyrimidine dehydrogenase activity: Prognostic partner of 5-fluorouracil? Clin Cancer Res 1999; 5: 1947-9.
8. Johnston P G, Drake J C, Trepel J, Allegra C J. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 1992; 52: 4306-12.
9. Van der Wilt C L, Pinedo H M, Smid K, Peters G J. Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. Cancer Res 1992; 52: 4922-8.
10. Kuniyasu T, Nakamura T, Tabuchi Y, Kuroda Y. Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody: The clinical role of thymidylate synthase as a prognostic indicator and its therapeutic usefulness. Cancer 1998; 83: 1300-6.
11. Edler D, Glimelius B, Hallstrom M et al. Thymidylate synthase expression in colorectal cancer: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2002; 20: 1721-8.
12. Hu Y C, Komorowski R A, Graewin S et al. Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer. Clin Cancer Res 2003; 9: 4165-71.
13. Mizutani Y, Wada H, Ogawa O et al. Prognostic significance of thymidylate synthase activity in bladder carcinoma. Cancer 2001; 92: 510-8.
14. Allegra C J, Parr A L, Wold L E et al. Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 2002; 20: 1735-43.
15. Aschele C, Debernardis D, Casazza S et al. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 1999; 17: 1760-70.
16. Harpole D H Jr, Moore M B, Herndon J E 2nd et al. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2001; 7: 562-9.
17. Yokota H, Fernandez-Salguero P, Furuya H et al. cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria. J Biol Chem 1994; 269: 23192-6.
18. Beck A, Etienne M C, Cheradame S et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 1994; 30A: 1517-22.
19. Fischel J L, Formento P, Etienne M C, Spector T, Renee N, Milano G. Dual modulation of 5-fluorouracil cytotoxicity using folinic acid with a dihydropyrimidine dehydrogenase inhibitor. Biochem Pharmacol 1997; 53: 1703-9.
20. Ishikawa Y, Kubota T, Otani Y et al. Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice. Clin Cancer Res 1999; 5: 883-9.
21. Salonga D, Danenberg K D, Johnson M et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6: 1322-7.
22. Ichikawa W, Uetake H, Shirota Y et al. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 2003; 9: 786-91.
23. Leichman C G, Lenz H J, Leichman L et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997; 15: 3223-9.
24. Terashima M, Fujiwara H, Takagane A et al. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer. Gastric Cancer 2003; 6: 71-81.
25. Fujii R, Seshimo A, Kameoka S. Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma. Int J Clin Oncol 2003; 8: 72-8.
26. Isshi K, Sakuyama T, General T et al. Predicting 5-FU sensitivity using human colorectal cancer specimens: Comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU. Int J Clin Oncol 2002; 7: 335-42.
27. Ichikawa W, Uetake H, Shirota Y et al. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 2003; 89: 1486-92.
28. Metzger R, Danenberg K, Leichman C G et al. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 1998; 4: 2371-6.
29. Miyazaki K, Shibahara T, Sato D et al. Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines. J Gastroenterol 2006; 41: 140-50.
30. Nishiyama M, Yamamoto W, Park J S et al. Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res 1999; 5: 2620-8.
31. Kim R, Tanabe K, Inoue H, Toge T. Mechanism (s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma. Int J Oncol 2002; 20: 549-55.